Bioanalytical Systems Incorporated (NASDAQ:BASI) Reports Increase in Sellers; Strong Momentum for Short Players

December 8, 2017 - By Michael Collier

 Bioanalytical Systems Incorporated (NASDAQ:BASI) Reports Increase in Sellers; Strong Momentum for Short Players

Investors sentiment decreased to 2.67 in Q2 2017. Its down 0.33, from 3 in 2017Q1. It dropped, as 2 investors sold Bioanalytical Systems, Inc. shares while 1 reduced holdings. 4 funds opened positions while 4 raised stakes. 330,812 shares or 7.23% more from 308,517 shares in 2017Q1 were reported.
Acadian Asset Mngmt Ltd Liability Company holds 12,193 shares or 0% of its portfolio. State Street holds 10,200 shares. National Bank & Trust Of America Corp De holds 0% of its portfolio in Bioanalytical Systems, Inc. (NASDAQ:BASI) for 52 shares. Barclays Public Lc owns 83 shares. New York-based Morgan Stanley has invested 0% in Bioanalytical Systems, Inc. (NASDAQ:BASI). New York-based Renaissance Technology Ltd Liability has invested 0% in Bioanalytical Systems, Inc. (NASDAQ:BASI). 2,791 were reported by Blackrock. Jpmorgan Chase has invested 0% in Bioanalytical Systems, Inc. (NASDAQ:BASI). Citadel Advsrs Limited Liability Corporation stated it has 0% in Bioanalytical Systems, Inc. (NASDAQ:BASI). Panagora Asset Management has 12,309 shares. Vanguard Gru holds 0% of its portfolio in Bioanalytical Systems, Inc. (NASDAQ:BASI) for 112,296 shares. North Star Asset Incorporated accumulated 20,000 shares. Bridgeway Cap Inc accumulated 24,610 shares or 0% of the stock.

The stock of Bioanalytical Systems Incorporated (NASDAQ:BASI) registered an increase of 23.55% in short interest. BASI’s total short interest was 32,000 shares in December as published by FINRA. Its up 23.55% from 25,900 shares, reported previously. With 42,100 shares average volume, it will take short sellers 1 days to cover their BASI’s short positions. The short interest to Bioanalytical Systems Incorporated’s float is 0.49%.

The stock increased 2.54% or $0.07 during the last trading session, reaching $2.83. About 117,216 shares traded or 118.96% up from the average. Bioanalytical Systems, Inc. (NASDAQ:BASI) has risen 61.39% since December 8, 2016 and is uptrending. It has outperformed by 44.69% the S&P500.

Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, other North America, the Pacific Rim, Europe, and internationally. The company has market cap of $23.32 million. It operates in two divisions, Contract Research Services and Research Products. It currently has negative earnings. The Contract Research Services segment offers screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing services.

More news for Bioanalytical Systems, Inc. (NASDAQ:BASI) were recently published by: Marketwatch.com, which released: “Bioanalytical Systems Inc.” on December 21, 2009. Businesswire.com‘s article titled: “Bioanalytical Systems, Inc. Announces Appointment of New Chief Financial Officer” and published on May 11, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: